|
Samaritan Breast Cancer Diagnostic |
Jan 04, 2008 -- /prbuzz/ --Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today it has received a notice that the United States patent, Title: Peripheral-Type Benzodiazepine Receptor: A tool for detection, diagnosis, prognosis, and treatment of cancer was formally allowed on April 9, 2007. U.S. Patent Application Serial Number: 09/047,652.
Samaritan's diagnostic kit is comprised of antibodies against PBR suitable for use in detecting the presence of an aggressive breast cancer tumor. This patent's claims are related to a biopsy test. Samaritan has also filed another application for a blood test against the same marker.
The patent has been awarded to Georgetown University and is exclusively licensed to Samaritan.
See peer reviewed journal publications:
http://www.samaritanpharma.com/publications_and_patents.asp
About Samaritan Pharmaceuticals: ``We LIV... to Save Lives.''
Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company, focused on commercializing innovative therapeutic products to relieve the suffering of patients with Alzheimer's disease; cancer; cardiovascular disease, HIV, and Hepatitis C. Samaritan partnered its “oral” entry inhibitor HIV drug SP-01A, with Pharmaplaz, Ireland; and is evaluating the use of Caprospinol, SP-233 for Alzheimer's disease patients; the use of SP-1000 for acute coronary disease patients; and the use of SP-10T1 as an "oral treatment" for Hepatitis-C patients. In addition, Samaritan has acquired the marketing and sales rights to sell nine revenue-generating products in Greece and/or various Eastern European countries. Website, http://www.samaritanpharma.com. Please register so we can notify you of upcoming conference calls, news and events.
Disclaimer:
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
|
About the Press Release
Samaritan's diagnostic kit is comprised of antibodies against PBR suitable for use in detecting the presence of an aggressive breast cancer tumor. This patent's claims are related to a biopsy test.
|
|
|
Download PDF Version
Email this story to a colleague
Printer Friendly Version
